entertainment -WSS

entertainment

author：entertainment 2025-08-28 13:07:18 - browse：41

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Fetal surgery at risk from Dobbs and new abortion restrictions

WSS

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

AstraZeneca lung cancer study comes in below expectations

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Takeda, Janssen join wearable maker to measure scratching

Dexcom's push to bring CGM to type 2 diabetes patients

The EPA's new lead rule: How one expert crunched the numbers

focus

entertainment

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AstraZeneca lung cancer study comes in below expectations

Activists slam private health insurers over coverage restrictions

Takeda, Janssen join wearable maker to measure scratching

The high cost of giving birth even with insurance

Crowdfunding for unproven stem cell procedures spreads misinformation

At least 13 dead in Texas as scorching temps continue

How to pay for weight loss drugs and save Medicare

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cigna, Humana reportedly in talks to merge

focus

Use doctors trained outside the U.S. to ease the physician shortage

A letter from the executive editor: The 2023 STATUS List

Security flaws in third

BIO selects John Crowley as new CEO

Hubble vs. James Webb telescope images: See the difference

How Robert F. Kennedy Jr. distorted vaccine science

knowledge

focus

hotspot

hotspot